Table 2. Summary of phase II trials using a single-agent taxane in patients with hormone-refractory prostate cancer.
| Author | Taxane regimen | N | Median age (yrs) | >50% PSA decline | Response in measurable disease | TTP | Survival |
|---|---|---|---|---|---|---|---|
| Picus and Shultz (1999) | Docetaxel 75 mg m−2 q 3 wk | 35 | 70 | 46% | 28% (7/25) | 9 m | 27 m |
| Friedland et al (1999) | Docetaxel 75 mg m−2 q 3 wk | 16 | 69 | 38% | 66% (6/9) | NR | NR |
| Berry et al (2001) | Docetaxel 36 mg m−2 wk−1 × 6 of an 8-wk cycle | 59 | 72 | 41% | 33% (2/6) | 5.1 m | 9.4 m |
| Beer et al (2001) | Docetaxel 36 mg m−2 wk−1 × 6 of an 8-wk cycle | 24 | 72 | 46% | 40% (2/5) | NR | NR |
| Trivedi et al (2000) | Paclitaxel 150 mg m−2 wk−1 | 18 | 69 | 39% | 50% (4/8) | NR | NR |
N=number of patients; NR=not reported; PSA=prostate-specific antigen; q=every; TTP=time to progression; wk=week; yrs=years; q=every.